株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ImmunoVaccine Technologies Inc. - 製品パイプライン分析

Immunovaccine, Inc. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 192653
出版日 ページ情報 英文 40 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.54円で換算しております。
Back to Top
ImmunoVaccine Technologies Inc. - 製品パイプライン分析 Immunovaccine, Inc. - Product Pipeline Review - 2016
出版日: 2016年07月13日 ページ情報: 英文 40 Pages
概要

ImmunoVaccine Technologies Inc. はカナダに本社を置くバイオテクノロジー企業で、癌治療用および感染症、家畜用ワクチンの開発・販売を行っています。 同社の製品であるDPX-0907は癌細胞を認識し攻撃するための免疫システムを活性化させるワクチンです。

当レポートでは、Cosmo Pharmaceuticals S.p.Aにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

ImmunoVaccine Technologies Inc. の基本情報

  • ImmunoVaccine Technologies Inc. の概要
  • 主要情報
  • 企業情報

ImmunoVaccine Technologies Inc. :R&Dの概要

  • 主な治療範囲

ImmunoVaccine Technologies Inc. :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

ImmunoVaccine Technologies Inc. :パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第?相の製品/併用療法モダリティ
    • 第?相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ

ImmunoVaccine Technologies Inc. :薬剤プロファイル

  • DPX-0907
  • DPX-Survivac
  • DPX-RSV
  • Vaccine for Cocaine Addiction
  • DPX-Ebola
  • hepatitis B vaccine
  • influenza strain H5N1 vaccine
  • malaria vaccine
  • pertussis (acellular) vaccine
  • dengue vaccine
  • herpes simplex virus type 2 vaccine
  • marburg vaccine
  • tuberculosis vaccine

ImmunoVaccine Technologies Inc. :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

ImmunoVaccine Technologies Inc. :最新のパイプライン情報

ImmunoVaccine Technologies Inc. :開発休止中のプロジェクト

ImmunoVaccine Technologies Inc. :開発が中止された製品

  • 開発が中止された製品のプロファイル

ImmunoVaccine Technologies Inc. :本社と子会社の所在地

  • 本社

付録

図表一覧

目次
Product Code: GMDHC08086CDB

Summary:

Global Markets Direct's, 'Immunovaccine, Inc. - Product Pipeline Review - 2016', provides an overview of the Immunovaccine, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Immunovaccine, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the pipeline therapeutic landscape of Immunovaccine, Inc.
  • The report provides overview of Immunovaccine, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Immunovaccine, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Immunovaccine, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy:

  • Evaluate Immunovaccine, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Immunovaccine, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Immunovaccine, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Immunovaccine, Inc. Snapshot
    • Immunovaccine, Inc. Overview
    • Key Information
    • Key Facts
  • Immunovaccine, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Immunovaccine, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Immunovaccine, Inc. - Pipeline Products Glance
    • Immunovaccine, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Immunovaccine, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Immunovaccine, Inc. - Drug Profiles
    • DPX-Survivac
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DPX-RSV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Cocaine Addiction
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DPX-Ebola
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DPXE-7
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • malaria vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Zika virus vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Immunovaccine, Inc. - Pipeline Analysis
  • Immunovaccine, Inc. - Pipeline Products by Target
  • Immunovaccine, Inc. - Pipeline Products by Route of Administration
  • Immunovaccine, Inc. - Pipeline Products by Molecule Type
  • Immunovaccine, Inc. - Recent Pipeline Updates
  • Immunovaccine, Inc. - Dormant Projects
  • Immunovaccine, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • Pseudomonas vaccine
  • Immunovaccine, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Immunovaccine, Inc., Key Information
  • Immunovaccine, Inc., Key Facts
  • Immunovaccine, Inc. - Pipeline by Indication, 2016
  • Immunovaccine, Inc. - Pipeline by Stage of Development, 2016
  • Immunovaccine, Inc. - Monotherapy Products in Pipeline, 2016
  • Immunovaccine, Inc. - Partnered Products in Pipeline, 2016
  • Immunovaccine, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • Immunovaccine, Inc. - Out-Licensed Products in Pipeline, 2016
  • Immunovaccine, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Immunovaccine, Inc. - Phase II, 2016
  • Immunovaccine, Inc. - Phase I, 2016
  • Immunovaccine, Inc. - Preclinical, 2016
  • Immunovaccine, Inc. - Pipeline by Target, 2016
  • Immunovaccine, Inc. - Pipeline by Route of Administration, 2016
  • Immunovaccine, Inc. - Pipeline by Molecule Type, 2016
  • Immunovaccine, Inc. - Recent Pipeline Updates, 2016
  • Immunovaccine, Inc. - Dormant Developmental Projects,2016
  • Immunovaccine, Inc. - Discontinued Pipeline Products, 2016

List of Figures

  • Immunovaccine, Inc. - Pipeline by Top 10 Indication, 2016
  • Immunovaccine, Inc. - Pipeline by Stage of Development, 2016
  • Immunovaccine, Inc. - Monotherapy Products in Pipeline, 2016
  • Immunovaccine, Inc. - Partnered Products in Pipeline, 2016
  • Immunovaccine, Inc. - Pipeline by Target, 2016
  • Immunovaccine, Inc. - Pipeline by Route of Administration, 2016
  • Immunovaccine, Inc. - Pipeline by Molecule Type, 2016
Back to Top